U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN
The Dermatology Digest
FEBRUARY 18, 2025
The U.S. Food and Drug Administration (FDA) approved mirdametinib (Gomekli, SpringWorks) for the treatment of adult and pediatric patients aged two and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. Gomekli is an oral, small molecule MEK inhibitor. NF1 is a genetic disorder that currently affects approximately 100,000 children and adults in the United States.Patients with NF1 have approximately a 30-50% lif
Let's personalize your content